Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations

Author： Haznedaroglu Ibrahim C  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.15, 2013-10, pp. : 2005-2010

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Stem Cell Transplantation for Chronic Myeloid Leukemia (CML): Current Indications and Perspectives

By  

Current Cancer Drug Targets, Vol. 13, Iss. 7, 2013-01 ,pp. : 775-778

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment options for chronic myeloid leukemia

By Tanaka Maria Florencia   Kantarjian Hagop   Cortes Jorge   Ohanian Maro   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 815-828

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for chronic myeloid leukemia

By Cilloni Daniela   Messa Emanuela   Rotolo Antonia   Saglio Giuseppe  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. : 175-184

Informa Healthcare

Access to resources Recommend Favorite

Emerging Therapies in Chronic Myeloid Leukemia

By  

Current Cancer Drug Targets, Vol. 12, Iss. 5, 2012-05 ,pp. : 458-470

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Drugs in Chronic Myeloid Leukemia

By  

Current Medicinal Chemistry, Vol. 15, Iss. 29, 2008-12 ,pp. : 3036-3051

Bentham Science Publishers

Access to resources Recommend Favorite